As we reported that both YY1 and EZH2 were overexpressed in breast cancer cells and cancers versus normal mammary samples, blocking EZH2 recruitment by YY1 would cause more pronounced adverse effects in tumor cells than those in normal cells, implicating the relatively low side effects of this strategy. This evidence concerns the gene EZH2 and cancer.